Extremity and non-extremity high-grade osteosarcoma: The Norwegian Radium Hospital experience during the modern chemotherapy era

Acta Oncologica

Volumn 35, Issue SUPPL. 8, 1996, Pages 129-134

  Sæter, Gunnar ^a   Bruland, Øyvind S ^a   Follerås, Gunnar ^a   Boysen, Morten ^a   Høie, Johan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOSARCOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CLINICAL TRIALS; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NORWAY; OSTEOSARCOMA;

EID: 0030434058     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098531     Document Type: Article

References (16)

1. Harvei S, Solheim Ø. The prognosis in osteosarcoma: Norwegian national data. Cancer 1981; 48: 1719-23.
2. Sæter G, Alvegård TA, Elomaa I, Stenwig AE, Holmström T, Solheim ØP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
3. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
4. Winkler K, Bieling P, Bielack S, et al. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop 1991; 270: 79-86.
5. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227-38.
6. Bertoni F, Dallera P, Bacchini P, Marchetti C, Campobassi A. The Istituto Rizzoli-Beretta experience with osteosarcoma of the jaw. Cancer 1991; 68: 1555-63.
7. Shin K-H, Rougraff BT, Simon MA. Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop 1994; 304: 207-17.
8. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.
9. Fahey M, Spanier SS, Vander Griend RA. Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients. J Bone Joint Surg Am 1992; 74: 321-30.
10. Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim ØP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084-93.
11. Smeele LE, Van der Wal JE, Van Diest PJ, Van der Waal I, Snow GB. Radical surgical treatment in craniofacial osteosarcoma gives excellent survival. A retrospective cohort study of 14 patients. Eur J Cancer [B] 1994; 30B: 374-6.
12. Bruland ØS, Pihl A. Immunoscintigraphy and radioimmunotherapy. Useful approaches in the management of osteogenic sarcoma? In: Novak J, ed. Frontiers of osteosarcoma research. Hogrefe and Huber, 1993: 149-59.
13. Bruland ØS, Aas M, Solheim ØP, Winderen M, Høie J. Treatment of metastatic disease in osteosarcoma patients. New applications of radiolabelled poly- and bisphosphonates. Bone and Mineral 1994; 25: 78.
14. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/ Austrian study. J Clin Oncol 1984; 2: 617-24.
15. Strander H, Bauer HC, Brosjö O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995; 34: 877-80.
16. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia S-F, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother 1995; 17: 181-93.